Skip to main content

Table 2 TIL increase during neoadjuvant letrozole in postmenopausal breast cancer patients (n = 106)

From: Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial

 Changep
Overall increase, mean (range)6.8 (− 39 to 60)< 0.0001
Responders (n = 58)3.2 (− 39 to 35)0.10
Non-responders (n = 44)10.6 (− 25 to 60)< 0.0001
  1. TILs tumour-infiltrating lymphocytes